Sanofi (SNY) Rating Reiterated by J P Morgan Chase & Co
Sanofi (NYSE:SNY)‘s stock had its “neutral” rating restated by investment analysts at J P Morgan Chase & Co in a report released on Thursday.
A number of other analysts have also recently weighed in on SNY. upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a research note on Wednesday, August 30th. Argus reiterated a “buy” rating and set a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, November 15th. Finally, Morgan Stanley cut shares of Sanofi from an “overweight” rating to an “underweight” rating in a research note on Friday, December 1st. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $53.50.
Shares of Sanofi (NYSE SNY) traded down $0.83 during trading hours on Thursday, reaching $43.09. 2,169,232 shares of the company were exchanged, compared to its average volume of 1,497,251. The firm has a market cap of $110,700.00, a PE ratio of 13.87, a P/E/G ratio of 2.61 and a beta of 0.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.16 and a current ratio of 1.59. Sanofi has a 12-month low of $38.45 and a 12-month high of $50.65.
ILLEGAL ACTIVITY WARNING: “Sanofi (SNY) Rating Reiterated by J P Morgan Chase & Co” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/14/sanofi-sny-rating-reiterated-by-j-p-morgan-chase-co.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.